Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.69 - $1.21 $56,504 - $99,088
-81,891 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$1.02 - $3.8 $83,528 - $311,185
81,891 New
81,891 $97,000
Q4 2021

Feb 14, 2022

SELL
$3.26 - $4.66 $598,050 - $854,881
-183,451 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$4.08 - $5.66 $460,852 - $639,319
-112,954 Reduced 38.11%
183,451 $820,000
Q2 2021

Aug 13, 2021

BUY
$5.01 - $7.48 $1.48 Million - $2.22 Million
296,405 New
296,405 $1.62 Million
Q1 2021

May 17, 2021

SELL
$7.19 - $14.95 $333,781 - $694,023
-46,423 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$6.66 - $14.66 $309,177 - $680,561
46,423 New
46,423 $504,000
Q3 2020

Nov 16, 2020

SELL
$8.69 - $14.47 $212,540 - $353,907
-24,458 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$5.21 - $11.03 $127,426 - $269,771
24,458 New
24,458 $261,000
Q2 2018

Aug 14, 2018

SELL
$10.16 - $13.65 $133,096 - $178,815
-13,100 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$9.47 - $12.98 $124,057 - $170,038
13,100 New
13,100 $170,000

About Syros Pharmaceuticals, Inc.


  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $4.25M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.